GSK Plans Next-Generation Restless Legs Treatment Filing In Q3 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. drug maker also is planning to initiate a Phase III program evaluating GSK 1838262 for migraine prophylaxis.
You may also be interested in...
FDA Clears GSK’s Requip XL For Parkinson’s
Once-daily version is designed to battle generic competitors.
FDA Clears GSK’s Requip XL For Parkinson’s
Once-daily version is designed to battle generic competitors.
GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug
Positive efficacy with 600 mg a "surprise," XenoPort CEO says.